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Abstract 24 
Background 25 
Despite a steady stream of headlines suggesting they will transform the future of healthcare, 26 
high-tech regenerative medicines have, to date, been quite inaccessible to patients; only eight 27 
have been granted an EU marketing licence in the last seven years. Here, we outline some of 28 
the historical reasons for this paucity of licensed innovative regenerative medicines. We 29 
discuss the challenges to be overcome to expedite the development of this complex and 30 
rapidly changing area of medicine, together with possible reasons to be more optimistic for 31 
the future. 32 
Discussion  33 
Several factors have contributed to the scarcity of cutting-edge regenerative medicines in 34 
clinical practice. These include the great expense and difficulties involved in planning how 35 
individual therapies will be developed, manufactured to commercial levels, and ultimately 36 
successfully delivered to patients. Specific challenges also exist when evaluating the safety, 37 
efficacy and cost-effectiveness of these therapies. Furthermore, many treatments are used 38 
without a licence from the EMA - under “Hospital Exemption” from the EC legislation. For 39 
products which are licensed, alternative financing approaches by healthcare providers may be 40 
needed, since many therapies will have significant up-front costs but uncertain benefits and 41 
harms in the long-term. 42 
However, increasing political interest and more flexible mechanisms for licensing and paying 43 
for therapies are now evident. These could be key to the future growth and development of 44 
regenerative medicine in clinical practice. 45 
3 
 
Conclusions 46 
Recent developments in regulatory processes, coupled with increasing political interest may 47 
offer some hope for improvements to the long and often difficult routes from laboratory to 48 
marketplace for leading-edge cell or tissue therapies. Collaboration between publicly-funded 49 
researchers and the pharmaceutical industry could be key to the future development of 50 
regenerative medicine in clinical practice; such collaborations might also offer a possible 51 
antidote to the innovation crisis in the pharmaceutical industry. 52 
 53 
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 55 
Background 56 
‘Cure for blindness found’ proclaimed a front page headline of a UK newspaper.[1] The 57 
article’s text revealed a different story, of a promising line of research based on clinical trial 58 
data from just a single patient treated with an embryonic stem cell therapy, for which it ‘will 59 
be some months before the full impact of it [the treatment] on her sight is known’. Although 60 
the fullness of time may yet reveal this new treatment to be a cure for blindness, this example 61 
illustrates the weight of expectation often placed on innovative new ‘regenerative medicines’ 62 
to transform the future of healthcare. Regenerative medicine - which is not a new field of 63 
medicine as it encompasses bone marrow or organ transplants - deals with the process of 64 
replacing or regenerating human cells, tissues or organs to restore or establish normal 65 
function.[2] Most new regenerative medicines will be classed by the European Medicines 66 
Agency (EMA) as being ‘advanced-therapy medicinal products’ (ATMPs) which are 67 
engineered regenerative medicines, and which encompass cell-based therapies (often using 68 
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stem cells or progenitor cells to produce tissues), gene therapies, and tissue-engineered 69 
therapies. 70 
The Committee for Advanced Therapies (CAT) is the EMA committee responsible for 71 
assessing the quality, safety and efficacy of ATMPs (and for following scientific 72 
developments in the field). Several EMA regulatory pathways exist which facilitate 73 
accelerated access to treatments where there is unmet patient need. These include: approval 74 
under exceptional circumstances (1993), conditional marketing authorisation (2005), 75 
accelerated assessment (2005), parallel scientific advice between EMA and FDA (2009) and 76 
the adaptive licensing pilot programme (2014). However, only eight ATMPs have been 77 
granted a marketing licence by the EMA: ChondroCelect (2009), Glybera (2012), MACI 78 
(2013), Provenge (2013), Holoclar (2015), Imlygic (2015), Strimvelis (2016) and Zalmoxis 79 
(2016), yet 318 relevant trials were performed in Europe between 2004 and 2010. The main 80 
sponsors were academic organisations, charities, and small companies - stakeholders who 81 
tend to have limited resources with regard to both financing and the capacity to navigate the 82 
required regulatory procedures.[3] This mismatch between the number of promising ideas 83 
and translation to actual patient benefit[4] may partly be due to key differences between 84 
regenerative medicines and conventional pharmaceuticals. Regenerative medicines are often 85 
truly personalised and therefore expensive and difficult to manufacture; evaluation of their 86 
efficacy, safety and cost-effectiveness may also be challenging.[5, 6]  87 
Nevertheless, there appears a new sense of urgency to address these issues. In the UK, a 88 
House of Lords Science and Technology Committee inquiry into regenerative medicine 89 
identified barriers to translation and commercialisation and recommended solutions. In 90 
response to its findings - published in 2013 - the National Institute for Health and Care 91 
Excellence (NICE) was asked to commission a study to assess whether its current appraisal 92 
methods and processes were appropriate to evaluate regenerative medicines. We were part of 93 
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the team which performed that study, which included an assessment of previous evaluations 94 
of regenerative medicines by NICE, the EMA and the Food and Drug Administration 95 
(FDA).[7, 8] More recently (in April 2016), the House of Commons Science and Technology 96 
Committee announced it was undertaking an inquiry into regenerative medicine, which will 97 
report in early February 2017. In this article we discuss some of the historical causes for the 98 
scarcity of licensed innovative regenerative medicines, together with possible reasons to be 99 
more optimistic for the future. This paper arose as a result of our work on the aforementioned 100 
study for NICE which was commissioned by the Regenerative Medicine Expert Group.  101 
Discussion 102 
The evidence-access trade-off 103 
Although the randomised controlled trial is the expected level of evidence for regulatory 104 
assessments, it is likely that many evidence submissions for regenerative medicines will 105 
comprise small, single-arm, short-term, early phase clinical trials. These sub-optimal study 106 
designs are likely to produce biased and imprecise results. However, the use of such designs 107 
is not inevitable and is unlikely to be through choice, but is instead a consequence of the type 108 
of patients targeted by new therapies. Populations with rare, severe or advanced disease may 109 
be very small, so adequate recruitment to trials with two treatment arms would require many 110 
centres, much time, and great expense. Also, where no alternative treatments exist, and 111 
patients have life-threatening or severe disease, randomisation to a control group is likely to 112 
be ethically unacceptable or problematic, as may the requirement for lengthy follow-up 113 
before licence submission. This is particularly likely to be a problem when initial studies on 114 
small numbers of patients have shown spectacular results.[9] Trials utilising alternative 115 
approaches to conventional randomisation might also be considered when rare diseases are 116 
studied.[10] For example, responsive-adaptive randomisation maximises allocation to the 117 
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most effective treatment and minimises the required sample size. Such a ‘play the winner’ 118 
design has the potential to reduce the number of patients allocated to less effective treatment 119 
therefore reducing the ethical concerns associated with randomisation, though it is limited to 120 
studies which assess rapidly available outcomes. However, for new types of study design 121 
such as this, the magnitude of the risks of bias are not yet well understood;[11] in reality 122 
single-arm studies are therefore most likely to be submitted for licensing purposes. 123 
Another issue often encountered is the use of surrogate endpoints - laboratory or 124 
physiological measures used to predict or provide an early measure of therapeutic effect - 125 
rather than real clinical (patient-important) endpoints. Surrogate endpoints data are quicker 126 
and easier to acquire than real clinic endpoint data, thus saving valuable time in the licensing 127 
process (for both manufacturers and patients) However, there is often considerable 128 
uncertainty about the strength of the relationship between a given surrogate and its relevant 129 
real clinical endpoint; this is problematic because trial results based on surrogate endpoints 130 
are not likely to be reliable if the surrogate has not been properly validated. It is therefore 131 
recommended that before a surrogate outcome is accepted, a systematic review should be 132 
conducted examining the evidence for the validation of the surrogate-final outcome 133 
relationship. To validate a surrogate endpoint such reviews must demonstrate there is 134 
adequate evidence from several sources: clinical trials, epidemiological/observational studies 135 
and pathophysiologic studies (of biological plausibility of the relationship).[12]  136 
 137 
Also, for those treatments studied in very specialised settings, scepticism about results may 138 
arise from evidence suggesting that single-centre trials tend to produce significantly larger 139 
effect estimates than multi-centre trials. A systematic review of 82 critical care medicine 140 
RCTs found significantly larger treatment effects for all-cause mortality in single-centre trials 141 
when compared with multi-centre trials (ratio of odds ratios, 0.64; 95% CI 0.4, to 0.87).[13] 142 
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Where ATMPs are likely to be delivered from more than just a single clinic site, efficacy 143 
results from single-centre trials should be considered cautiously by decision makers. 144 
 145 
The implications of such evidential problems will largely depend on both the level of unmet 146 
need in the studied population and the likeliness of cure or improvement without 147 
experimental treatment. This can be illustrated by comparing two quite recently licensed 148 
therapies which claimed to meet unmet patient needs: Holoclar (a stem cell-based therapy for 149 
treating corneal lesions resulting from burns to the eye) and Glybera (a gene therapy for 150 
treating familial lipoprotein lipase deficiency with associated pancreatitis). It seems Holoclar 151 
and Glybera had very different approval histories primarily due to differences in the 152 
likelihood of patient improvement without new therapy. Despite the clinical evidence for 153 
Holoclar being based on uncontrolled retrospective data, the results - around half the patients 154 
had improved visual acuity - were still sufficiently impressive for the EMA to grant a 155 
conditional licence on the first application. The prospective confirmatory study required as 156 
part of the EMA’s conditional approval should clarify Holoclar’s efficacy and safety.  157 
 158 
The application for Glybera was also supported by single-arm trial evidence. But while the 159 
evidence for Holoclar was deemed sufficiently robust, for Glybera there were concerns that 160 
the apparent treatment benefit may have been due to chance, resulting in Glybera’s long and 161 
protracted route to marketing authorisation. Negative committee opinions were issued in June 162 
2011, with approval finally granted in July 2012 with a more restrictive licence than was 163 
originally applied for. In 2015 the manufacturer of Glybera dropped plans to seek approval 164 
for the therapy in the U.S. following the FDA’s request for further clinical data. 165 
 166 
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As outlined earlier, the EMA has several regulatory pathways which attempt to create a 167 
balance between shorter approval times for promising medicines for populations with high 168 
unmet medical need, and ensuring a flow of evolving satisfactory information on efficacy and 169 
safety. The most recent update - the adaptive pathways pilot programme - utilises existing 170 
regulatory processes, and is a prospectively planned adaptive approach to bringing treatments 171 
to market with an initial focus on patients with high unmet need. It will be more of a 172 
staggered, iterative system than previous approval pathways. Such a ‘life-cycle approach’ to 173 
acquiring and (re)assessing evidence will consider the basis of decision making in the 174 
following stages of a product’s life cycle: development, licensing, reimbursement, 175 
monitoring/post-licence evidence and utilisation.[14, 15]  176 
Improvements to this life-span approach are developing at pace. For example, with MAPPs 177 
(Medicines Adaptive Pathways to Patients) the development plan across target populations 178 
and indications will be agreed up-front with the EMA. Plans may include a range of studies, 179 
such as RCTs, single-arm studies, pragmatic trials and other forms of real world study.[16] A 180 
newly formed public-private project called ADAPT SMART (Accelerated Development of 181 
Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to 182 
Treatment-outcomes), funded by the EU Innovative Medicines Initiative, is focused on laying 183 
the foundations for MAPPs to be put into practice in Europe. The challenge for ADAPT 184 
SMART is to develop an approach to adaptive pathways that aligns the needs of all 185 
stakeholders, including patients, member state payers, regulators, medical practitioners and 186 
industry.[17] Finally, the recent proposals for developing a more enabling environment for 187 
‘strategically important transformative products’ that the UK Department of Health (2016) 188 
has announced is regarded as an additional vehicle through which ATMPs might be fostered. 189 
Crucial to this will be the establishing of ‘accelerated access partnerships’ between public 190 
9 
 
and private sectors and the NHS of a form not seen before, suggesting that its success will 191 
depend as much on identifying transformative processes as much as products.[18] 192 
Development of ideas and scale-up to commercialisation 193 
Most new regenerative medicines are developed by academic research institutions or small- 194 
and medium-sized enterprises. Ideas for new therapies are not uncommon, but it is difficult 195 
for new centres to enter the field under existing regulations; producing regenerative 196 
medicines in accordance with good manufacturing practices - to ensure quality, safety and 197 
efficacy - is expensive and the ongoing costs are frequently overlooked by academic centres 198 
with no history of cell therapy manufacture. Successful academic centres are often those with 199 
pre-existing quality management systems and staff experienced in manufacturing more 200 
conventional cell therapy products (e.g. those relating to haematopoietic stem cell 201 
transplantation and lymphocyte infusion).[19]  202 
The wide variation evident across the types of new cell-based medicines[20] highlights the 203 
importance of careful consideration of how individual therapies will be developed, 204 
manufactured, and ultimately successfully delivered to patients in clinical practice settings to 205 
commercially viable levels. Key differences in issues will also arise depending on which of 206 
the two main types of cell is being used when developing a new therapy: autologous 207 
(bespoke) cell therapies, which are derived from an individual patient’s own cells and 208 
allogeneic (universal) cell therapies which are derived from a donor. A clear understanding of 209 
what will be needed for scale-up to commercial levels is particularly important. Autologous 210 
therapies have advantages over allogeneic therapies in terms of: smaller start-up costs, 211 
simpler regulations, the potential for point-of-care processing, and ease of obtaining cells (in 212 
terms of time and resources). Allogeneic therapies have advantages over autologous therapies 213 
in terms of: patient throughput, product consistency, quality control being applied to larger 214 
lots, and treatment delays from processing failures.[21] Of the eight ATMPs licensed to date, 215 
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five have been autologous, two have been viral gene therapies (Glybera and Imlygic) and one 216 
allogeneic (Zalmoxis). 217 
The Cell and Gene Therapy Catapult is an organisation dedicated to growing the UK cell and 218 
gene therapy industry by bridging the gap between academic research and full scale 219 
commercialisation. It promotes and develops the existing early phase manufacturing network; 220 
the UK's small-scale academic facilities are a good source of materials for early-stage clinical 221 
trials although they are expected to reach full capacity within a few years as the industry 222 
matures. With this in mind, the Catapults’ work will be augmented by a £55m large-scale 223 
manufacturing facility (due to open in 2017).[22] The centre aims to provide an infrastructure 224 
to enable the manufacture of allogeneic or autologous cell therapies for later phase (II or III) 225 
clinical trials and commercial scale-up. For developing businesses this will mean that 226 
finances need not be committed to a permanent commercial facility before it is known 227 
whether products are going to be both clinically useful and economically viable. The vision is 228 
that successful products will eventually be manufactured from purpose-built facilities 229 
operated by successful firms. Input from organisations such as the Cell and Gene Therapy 230 
Catapult could be crucial – company size appears to be an independent predictor of outcome 231 
of a marketing authorization application to the EMA: the smaller the company, the more 232 
likely a negative outcome. Direct interaction with regulators also appears to be a key 233 
predictor of success.[23] 234 
Reimbursement by healthcare systems and evaluation of cost-effectiveness  235 
How should we value and price therapies which might cure chronic or fatal diseases? How 236 
should we pay for them? Claims of long-term benefits (perhaps even cures), long-term safety 237 
issues due to persistence of therapeutic cells, and significant up-front costs are issues which 238 
raise particular challenges in the assessment of the cost-effectiveness of regenerative 239 
medicines. Even where there may be significant potential benefits over current therapies, 240 
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these may not be known with a high level of certainty at the time of licensing.[7, 8] 241 
Furthermore, a key difference between regenerative medicines and conventional medicines is 242 
the possibility that therapies may change over time. For example, when the ATMPs MACI 243 
and ChondroCelect (treatments for knee cartilage defects) were assessed by NICE they were 244 
third generation products. This may pose further uncertainty problems since by the time long-245 
term trial results become available, the particular studied therapy may well have been 246 
superseded by a (apparently superior) next-generation treatment. 247 
For EMA licensing purposes a sponsor must demonstrate a favourable benefit-risk balance. 248 
However, the level of evidence required to achieve this can be less than that needed to 249 
estimate the relative effectiveness compared to current practice, or to quantify long-term 250 
treatment benefits. Since this latter information is essential for reliable assessment of cost-251 
effectiveness, developers may find it is more difficult to demonstrate cost-effectiveness for 252 
reimbursement than it is to demonstrate efficacy for licensing. Schemes that allow 253 
development of further evidence or entail a risk-sharing component (between the payer and 254 
the manufacturer) may therefore be required. 255 
Managed entry agreements (MEAs) or performance-based risk sharing agreements (PBRSAs) 256 
are an increasingly common policy response for dealing with evidence base uncertainty. 257 
PBRSAs involve the performance of treatments being tracked in a defined patient population 258 
over a specified time period, with the level or continuation of reimbursement based on the 259 
health and economic outcomes achieved. PBRSAs fall under a variety of names and 260 
categories: outcomes-based schemes, risk-sharing agreements, coverage with evidence 261 
development, access with evidence development, conditional licensing and managed entry 262 
schemes. Patient access schemes (PASs) may also sometimes be linked to performance. 263 
There has always been much uncertainty about the ultimate real-world clinical and economic 264 
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performance of new products; PBRSAs represent one mechanism for reducing this 265 
uncertainty.[24]  266 
Concern surrounding the potential high up-front costs of regenerative medicines and their 267 
affordability to health care systems means that alternative financing approaches may also 268 
have to be considered. These include pay for performance, where the total price is more 269 
directly related to therapy performance in clinical practice, and amortisation, where payments 270 
are spread over the expected duration of benefits.[25] The appropriateness of employing 271 
different discount rates and/or different rates over time is also an area requiring careful 272 
consideration, particularly for potentially curative therapies.  273 
Successful adoption of newly licensed ATMPs may well depend on how they relate to 274 
existing clinical interventions. The manufacturer of ChrondroCelect - a licensed treatment for 275 
knee cartilage defects - recently announced the initiation of the withdrawal of marketing 276 
authorisation due to commercial reasons. The EMA’s marketing authorisation for MACI 277 
(also a therapy for knee cartilage defects) was suspended in September 2014 as an authorised 278 
manufacturing site no longer existed (the developer closed the site). A key issue here could 279 
be the availability of alternative, more cost-effective treatments: established treatments such 280 
as microfracture have long been available for repairing knee cartilage defects. More recently, 281 
in December 2016, the FDA gave marketing authorisation to MACI in the USA, and Vericel 282 
will now try to build a new market for this there. ATMPs are likely to be expensive and these 283 
examples suggest they may be most likely to succeed commercially where there is an unmet 284 
medical need. 285 
Remaining hurdles and uncertainties 286 
Despite some reasons to be more optimistic about the future of regenerative medicine, further 287 
challenges abound. One important issue is that many therapies are currently used without a 288 
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licence from the EMA under “Hospital Exemption” from the EC legislation (or via the 289 
“Specials” scheme in the UK). Such treatments are prepared on a non-routine basis according 290 
to specific quality standards and are used for individual patients in a hospital under the 291 
professional responsibility of a medical practitioner. The problem is that hospital exemptions 292 
are regulated at the national level, with different countries interpreting the legislation in 293 
different ways; harmonisation and clarity are needed in defining when treatments qualify. 294 
There is concern about a risk that a too broad use of hospital exemptions may deter the 295 
submission of marketing authorisation applications to the EMA.[26] 296 
Careful consideration of longer-term adverse effects profiles is also important, as they may 297 
not be straightforward. While many harms associated with pharmaceuticals may improve 298 
following discontinuation, for regenerative medicines there is the possibility of prolonged 299 
harms, especially where cells persist long-term. Developing effective methods for inducing 300 
immune tolerance of allogeneic therapies also remains a challenge. Patients receiving 301 
allogeneic cells may need long-term immune suppression to avoid rejection. More broadly, 302 
concerns have been raised that the evidence for benefits to patients of adaptive pathway 303 
approaches is lacking or contradictory.[27] There is also concern about the follow-up 304 
evidence for some treatments granted conditional approval by the EMA, with inconsistencies 305 
and delays in the fulfilment of specific obligations.[28, 29] 306 
The optimum approach for manufacturing autologous therapies is likely to be difficult to 307 
predict. Autologous therapies can be manufactured centrally although an example of the type 308 
of difficulties encountered with some centralised production models is provided by 309 
considering Provenge (sipuleucel-T), a cell-based immunotherapy for treating prostate 310 
cancer. The process involved patient cells being cold-shipped to a manufacturing site, where 311 
target immune cells were isolated and activated. These were then cold-shipped back to the 312 
patient, re-infused and the process repeated three times. The product handling and 313 
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manipulation was mostly manual which led to high product operating costs. Although efforts 314 
were made to reduce costs by automating some process stages, this example highlights the 315 
importance of considering functionally closed and automated scale-out processes early in 316 
clinical development.[30] In May 2015 the EU marketing authorisation for Provenge was 317 
withdrawn at the request of the manufacturer for commercial reasons. 318 
An alternative approach to producing autologous therapies centrally is scaling-out, rather than 319 
scaling-up (in a large facility). Historical successful examples of the creative use of existing 320 
multiple centres with technically-advanced facilities include organ, bone-marrow and stem-321 
cell transplants.[31] However, achieving a high level of product quality with decentralised 322 
models requires highly standardised, robust and transparent manufacturing processes and 323 
platforms.[32] In-hospital micro-factories are also prominent, particularly for autologous 324 
procedures that entail significant surgery/patient contact. Current examples include limbal 325 
stem cell transplantation and the bioengineered trachea. Nevertheless, whether multiple 326 
hospitals will be willing or able to commit to good manufacturing practice (GMP) under 327 
licence is untested. The UK moves towards ‘Cell and Gene Therapy Treatment Centres’ as 328 
recommended by the Advanced Therapies Manufacturing Taskforce (2016) poses new 329 
challenges for hospitals and the clinical science system more generally in designing new 330 
treatment infrastructures – with specific skills set, logistical and equipment demands and 331 
regulatory oversight – for ATMPs.[33] Centralised production of autologous therapies may 332 
be seen as more appropriate, as is currently happening with a therapy (CTL019) being 333 
developed by Novartis; CTL019 is one of a number of CAR (chimeric antigen receptor) T-334 
cell blood cancer therapies.  335 
Providing a good illustration of many of the issues raised in this article, CAR T-cell therapies 336 
are a regenerative medicine to watch out for in the near future. They may offer a potential 337 
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cure for very ill patients with high unmet medical needs - typically patients with 338 
refractory/relapsed leukaemia - though they have potentially serious adverse effects. 339 
In autologous CAR T-cell therapies a patient’s T-cells are genetically modified whereby the 340 
activated T-cells can attack and destroy leukaemia B-cells. These therapies have been under 341 
development for around 20 years, they are truly innovative and they have received much 342 
press attention due to very encouraging early phase trial results.[7] Such results mean that use 343 
of a randomised controlled design in further trials would not be ethical in the patient 344 
populations being studied. 345 
CAR T-cells are costly and complex to produce. For Novartis’s CTL019 the initial work was 346 
carried out in an academic setting with the treatments now being produced in centralised 347 
large scale facilities. This is in preparation for licensing trials and marketing authorisation. 348 
Interestingly, in terms of the viability and cost-effectiveness of manufacture, CTL019 is 349 
being produced in the same facility as (the aforementioned) Provenge was. However, there 350 
appear to be key differences between these therapies: the benefits from CTL019 seem likely 351 
to be much greater than those from Provenge and CTL019 is frozen-shipped, so 352 
transportation and timing issues should be minimised. Novartis bought the facility from 353 
Dendreon, the biotech company which used to manufacture Provenge.  354 
The CAR T-cell example also highlights the importance of adequately robust research both 355 
for marketing authorisation and beyond. When to treat with CAR T-cells, what pre-356 
conditioning is needed, and how to manage toxicity due to cell persistence are just some of 357 
the issues which will need resolving. 358 
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Conclusions 359 
Notwithstanding some challenges, the EMA’s recent approval of Strimvelis and the 360 
conditional approval of Holoclar provide examples of successful collaboration between 361 
publicly-funded researchers and the pharmaceutical industry.[34, 35] Such collaborations 362 
could be the antidote to the innovation crisis in the pharmaceutical industry, where much 363 
research is aimed at developing safe-bet “me too” drugs which offer little or no benefit over 364 
treatments already available.[36] Collaboration may allow closer attention to the patient 365 
pathway and reduce time to market by ensuring more straightforward adoption into clinical 366 
practice.[37] 367 
The more flexible regulatory landscape, more appropriate range of options for reimbursement  368 
and increasing political interest and support structures do suggest a brighter future for 369 
regenerative medicine - the licensing of four ATMPs between 2015 and 2016 attest to this. 370 
Nevertheless, only time will tell as to whether future ‘cure for blindness’ headlines reflect the 371 
probable, rather than the possible. 372 
 373 
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